229 related articles for article (PubMed ID: 26668577)
1. A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review.
Iida K; Kawai N; Naiki T; Etani T; Ando R; Nagai T; Sugiyama Y; Naiki-Ito A; Nishio H; Okada A; Kohri K; Yasui T
Case Rep Oncol; 2015; 8(3):530-5. PubMed ID: 26668577
[TBL] [Abstract][Full Text] [Related]
2. Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
Anraku T; Hashidate H; Nakahara A; Imai T; Kawakami Y
BMC Urol; 2023 Mar; 23(1):38. PubMed ID: 36934227
[TBL] [Abstract][Full Text] [Related]
3. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
4. Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report.
Miyama Y; Kanao K; Uranishi K; Hirasaki M; Yasuda M
Int Cancer Conf J; 2023 Jan; 12(1):24-30. PubMed ID: 36605848
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress.
Plimack ER; Geynisman DM
J Clin Oncol; 2016 Jun; 34(18):2088-92. PubMed ID: 27161964
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Consolidative and Salvage Radiotherapy for Lymph Node Metastasis in Upper Urinary Tract Urothelial Carcinoma.
Kondo H; Shirotake S; Okabe T; Makino S; Nishimoto K; Oyama M
Case Rep Urol; 2018; 2018():1471839. PubMed ID: 29850366
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
8. Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma.
Xu Z; Ma J; Chen T; Yang Y
Front Immunol; 2022; 13():978266. PubMed ID: 36458005
[TBL] [Abstract][Full Text] [Related]
9. Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers.
Qian T; Huang XE
Asian Pac J Cancer Prev; 2015; 16(11):4791-5. PubMed ID: 26107242
[TBL] [Abstract][Full Text] [Related]
10. Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report.
Yang R; Chen JX; Luo SH; Chen TT; Chen LW; Huang B
World J Clin Cases; 2023 Feb; 11(5):1165-1174. PubMed ID: 36874416
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous metastasis emerging during chemotherapy and progressing during immunotherapy for urothelial carcinoma.
Otsuka I; Ueno T; Terada N; Mukai S; Fukushima T; Kiwaki T; Nagano M
IJU Case Rep; 2021 Nov; 4(6):363-366. PubMed ID: 34755057
[TBL] [Abstract][Full Text] [Related]
12. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
Li T; Hu W; Jin L; Yin X; Kang D; Piao L
Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Gwynn ME; DeRemer DL
Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.
Cao JZ; Wu W; Pan JF; Wang HW; Jiang JH; Ma Q
Front Oncol; 2021; 11():643413. PubMed ID: 34109111
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy.
Naiki T; Etani T; Naiki-Ito A; Fujii K; Ando R; Iida K; Nagai T; Sugiyama Y; Nakagawa M; Kawai N; Yasui T
Case Rep Oncol; 2017; 10(3):1057-1064. PubMed ID: 29515396
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
Galsky MD; Mironov S; Iasonos A; Scattergood J; Boyle MG; Bajorin DF
Invest New Drugs; 2007 Jun; 25(3):265-70. PubMed ID: 17146733
[TBL] [Abstract][Full Text] [Related]
17. [Transurethral flexible ureteroscopic holmium laser resection for tumors of renal pelvis: 6 cases report and literature review].
Hao YC; Chen K; Liu YQ; Lu J; Xiao CL; Ma LL
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):816-821. PubMed ID: 30337741
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
19. Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy.
Kawahara T; Mochizuki T; Sugimura R; Izumi K; Kuroda S; Miyoshi Y; Nakaigawa N; Yao M; Tanabe M; Uemura H
Case Rep Oncol; 2019; 12(2):548-553. PubMed ID: 31427950
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
